Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and b...

Autores
Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC.
Fil: Vignaduzzo, Silvana Edit. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Castellano, Patricia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Kaufman, Teodoro Saul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Materia
EXPERIMENTAL DESIGN
HPLC-DAD
HPLC-UV
RP-HPLC
TRIPLE COMBINATION
VALIDATION
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/127120

id CONICETDig_3cc37c62dd1b0795efa6d932392323ab
oai_identifier_str oai:ri.conicet.gov.ar:11336/127120
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associationsVignaduzzo, Silvana EditCastellano, Patricia MargaritaKaufman, Teodoro SaulEXPERIMENTAL DESIGNHPLC-DADHPLC-UVRP-HPLCTRIPLE COMBINATIONVALIDATIONhttps://purl.org/becyt/ford/1.4https://purl.org/becyt/ford/1The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC.Fil: Vignaduzzo, Silvana Edit. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Castellano, Patricia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Kaufman, Teodoro Saul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaTaylor & Francis2011-11-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/127120Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul; Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations; Taylor & Francis; Journal of Liquid Chromatography and Related Technologies; 34; 19; 18-11-2011; 2383-23951082-6076CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/10826076.2011.591020info:eu-repo/semantics/altIdentifier/doi/10.1080/10826076.2011.591020info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:46:41Zoai:ri.conicet.gov.ar:11336/127120instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:46:41.34CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
spellingShingle Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
Vignaduzzo, Silvana Edit
EXPERIMENTAL DESIGN
HPLC-DAD
HPLC-UV
RP-HPLC
TRIPLE COMBINATION
VALIDATION
title_short Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title_full Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title_fullStr Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title_full_unstemmed Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
title_sort Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations
dc.creator.none.fl_str_mv Vignaduzzo, Silvana Edit
Castellano, Patricia Margarita
Kaufman, Teodoro Saul
author Vignaduzzo, Silvana Edit
author_facet Vignaduzzo, Silvana Edit
Castellano, Patricia Margarita
Kaufman, Teodoro Saul
author_role author
author2 Castellano, Patricia Margarita
Kaufman, Teodoro Saul
author2_role author
author
dc.subject.none.fl_str_mv EXPERIMENTAL DESIGN
HPLC-DAD
HPLC-UV
RP-HPLC
TRIPLE COMBINATION
VALIDATION
topic EXPERIMENTAL DESIGN
HPLC-DAD
HPLC-UV
RP-HPLC
TRIPLE COMBINATION
VALIDATION
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.4
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC.
Fil: Vignaduzzo, Silvana Edit. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Castellano, Patricia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Kaufman, Teodoro Saul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
description The novel triple combination between Amlodipine (AML), Hydrochlorothiazide (HCT), and Valsartan (VAL) provides a new option for treating hypertension. The development and validation of an HPLC method for their simultaneous determination in pharmaceutical combinations, employing experimental design strategies, is reported. The drugs were separated on a C18 column at 30° C, using a 38:62 (v/v) mixture of 30 mMphosphate buffer (pH 5.5) and MeOH as mobile phase, delivered at 1.0mLmin -1. Detection was performed at 234 nm. Despite the wide difference in analytes' concentrations, the method showed good linearity (r 2 > 0.995) in the ranges 7.0-13.0 μg mL -1, 17.6-32.8 μg mL -1, and 226.2-420.2 μg mL -1 for AML, HCT, and VAL, respectively, being specific (peak purity > 0.999), accurate (bias ofanalyte recoveries <2.0%), and precise (inter-and intra-day variations <2%). It was also robust to small changes inflow rate (±0.05 mL min -1), pH (±0.1 unit) and proportion of MeOH (±3%) in the mobile phase. The method was applied to the assay of AML, HCT, and VAL in tablets of their novel association and formulations containing the HCT-VAL and AML-VAL binary combinations. Copyright © Taylor & Francis Group, LLC.
publishDate 2011
dc.date.none.fl_str_mv 2011-11-18
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/127120
Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul; Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations; Taylor & Francis; Journal of Liquid Chromatography and Related Technologies; 34; 19; 18-11-2011; 2383-2395
1082-6076
CONICET Digital
CONICET
url http://hdl.handle.net/11336/127120
identifier_str_mv Vignaduzzo, Silvana Edit; Castellano, Patricia Margarita; Kaufman, Teodoro Saul; Development and validation of an HPLC method for the simultaneous determination of amlodipine, hydrochlorothiazide, and Valsartan in tablets of their novel triple combination and binary pharmaceutical associations; Taylor & Francis; Journal of Liquid Chromatography and Related Technologies; 34; 19; 18-11-2011; 2383-2395
1082-6076
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/10826076.2011.591020
info:eu-repo/semantics/altIdentifier/doi/10.1080/10826076.2011.591020
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083563208835072
score 13.22299